"The Hampton University Proton Therapy Institute will bring state-of-the-art cancer treatment to Virginia and will ease human suffering and save lives. The Institute will treat over 2000 patients a year and will focus primarily on prostate cancer, but will also treat patients with breast, lung, eye and paediatric cancers. The death rate from prostate cancer is 2,4 times higher in African American men", stated Hampton University President William R. Harvey.
"We are very pleased to have finalized the terms of the contract with Hampton University Proton Therapy Institute. It is again a recognition of the unique benefits our company and our integrated proton therapy system can bring. We are now very excited to start building this proton therapy centre in partnership with such a prestigious institution and to see the unique benefits of proton therapy made available to even more patients to the State of Virginia and the Mid-Atlantic States", stated Pierre Mottet, IBA's Chief Executive Officer.
The centre will take about 3 years to start operation, with the first patient expected to be treated in 2010. The proton therapy, related equipment and maintenance provided by IBA are worth over 70 million euro.
IBA is currently building four proton therapy centres in the world, two in the USA and two in Europe. With the addition of this one for the Hampton University Proton Therapy Institute, IBA is proving it is once again the world expert in proton therapy, capable of building multiple large facilities anywhere in the world.
At ASTRO 2007 in Los Angeles, the IBA booth created wide attention by the visitors of the American Society of Therapeutic Radiology and Oncology's 2007 tradeshow. The new design for gantry treatment rooms presented in a life-size scale attracted many people interested in proton or particle therapy. Embedded in this new treatment room design is the working place of a therapist installed with MedCom's VeriSuite-Particle software. Many visitors from different countries, future customers of the therapy centres that are already selected for installation of VeriSuite-Particle as well as others interested in technical innovation informed themselves about MedCom's software for patient positioning in particle therapy.
MedCom, based in Darmstadt, Germany, manufactures and markets leading edge technology for clinical imaging with emphasis on telemedicine, radiology, cardiology, cancer treatment and ultrasound. The company is a partner of IBA. The development for its VeriSuite patient position verification system was already started in 2003. It is now prepared for a large range of treatment room configurations such as fixed beam treatment rooms - e.g. for head and neck treatments - and treatment rooms with a rotating gantry with up to three radiographic axis for verification.
The high accuracy, high degree of automation, intuitive user interface and fast calculations of 6 degrees of freedom (DoF) as well as DICOM network connectivity are only some of the technical characteristics of the system. Major vendors of particle therapy systems as well as other treatment centres use this software for their treatment rooms. Soon treatment centres in three continents will be equipped with MedCom's technology.
And once started, the further development of the company's systems is a continuous process: supervision of the patient position during the treatment is a real hot issue where MedCom will provide solutions in a future version. More MedCom news can be found in the VMW June 2007 article MedCom to release innovate software and tools for cancer treatment.
IBA delivers solutions of exceptional precision in the fields of cancer diagnosis and therapy. The company also provides sterilization and ionization solutions to improve the hygiene and safety of everyday life. IBA is listed on the pan-European stock exchange EURONEXT and belongs to the BelMid index. More company information is available at the IBA web site.